NASDAQ$VNDA
Vanda Pharmaceuticals Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Vanda reported financial results for the first quarter ended March 31, 2022.
Vanda Pharmaceuticals reported a decrease in total net product sales to $60.2 million, a 4% decrease compared to the first quarter of 2021. The company experienced a net loss of $6.4 million compared to a net income of $8.7 million in the same period last year.
- Total net product sales from HETLIOZ® and Fanapt® decreased by 4% to $60.2 million.
- HETLIOZ® net product sales decreased by 6% to $37.0 million.
- Fanapt® net product sales decreased by 1% to $23.2 million.
- Net loss was $6.4 million compared to net income of $8.7 million in the first quarter of 2021.
Headline financials
Revenue & EPS history
Vanda · Revenue · Quarterly
$60.2M
Revenue by segment
Vanda · $60.2M total across 2 segments · Q1 2022
- HETLIOZ$37M—61.5%
- Fanapt$23.2M—38.5%
Forward guidance
Vanda expects to achieve total revenues between $240 to $280 million, HETLIOZ® net product sales between $150 to $180 million, Fanapt® net product sales between $90 to $100 million and year-end 2022 cash greater than $440 million.
Tailwinds
- Total revenues between $240 to $280 million.
- HETLIOZ® net product sales between $150 to $180 million.
- Fanapt® net product sales between $90 to $100 million.
- Year-end 2022 cash greater than $440 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
-0.7%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+1.9%
Avg return
30 days after
45%
29 / 65 earnings
Positive
+24.8%
Q2 2019
Best reaction
-23.7%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -10.5% | -13.8% | -19.1% | |
| Q4 2025 | -17.6% | -16.6% | +18.6% | |
| Q3 2025 | -0.9% | -1.4% | +21.4% | |
| Q1 2025 | -3.9% | -9.1% | +5.3% | |
| Q4 2024 | -6.0% | -3.2% | +6.0% | |
| Q3 2024 | +4.8% | +11.5% | +1.0% | |
| Q2 2024 | -3.4% | -9.1% | -9.4% | |
| Q1 2024 | -8.6% | -7.8% | +11.7% | |
| Q4 2023 | +9.1% | +16.1% | +3.8% | |
| Q3 2023 | -23.7% | -23.0% | -15.1% | |
| Q2 2023 | -8.8% | -13.4% | -14.3% | |
| Q1 2023 | +7.0% | +7.9% | -5.6% | |
| Q4 2022 | -4.6% | -4.5% | -18.0% | |
| Q3 2022 | -4.8% | -0.2% | +2.5% | |
| Q2 2022 | -1.2% | +0.9% | -0.5% | |
| Q1 2022 | -6.2% | -0.1% | -0.8% | |
| Q4 2021 | -5.0% | -15.2% | -14.5% | |
| Q3 2021 | -11.8% | -11.9% | -21.2% | |
| Q2 2021 | -7.4% | -12.4% | -10.5% | |
| Q1 2021 | +5.1% | +7.2% | +8.6% | |
| Q4 2020 | +20.5% | +17.6% | +15.5% | |
| Q3 2020 | +3.8% | +3.5% | +17.2% | |
| Q2 2020 | +6.2% | +10.2% | -5.3% | |
| Q1 2020 | -4.4% | +0.4% | -2.5% | |
| Q4 2019 | -3.7% | -6.2% | -20.5% | |
| Q3 2019 | +7.6% | +10.2% | +29.4% | |
| Q2 2019 | +24.8% | +21.2% | +11.4% | |
| Q1 2019 | -3.1% | +1.3% | -9.9% | |
| Q4 2018 | +9.3% | +14.7% | -0.7% | |
| Q3 2018 | +16.7% | +12.5% | +37.2% | |
| Q2 2018 | +4.1% | +2.4% | -7.3% | |
| Q1 2018 | +10.6% | +11.0% | +25.1% | |
| Q4 2017 | +6.6% | +7.9% | +4.7% | |
| Q3 2017 | -16.8% | -16.5% | -11.7% | |
| Q2 2017 | +7.1% | +3.5% | +11.3% | |
| Q1 2017 | -0.3% | -3.3% | -8.0% | |
| Q4 2016 | -0.7% | +2.7% | -1.7% | |
| Q3 2016 | -8.4% | -2.3% | +4.7% | |
| Q2 2016 | +2.7% | +8.5% | +36.9% | |
| Q1 2016 | +3.9% | — | — | |
| Q4 2015 | -0.6% | — | — | |
| Q3 2015 | -9.5% | — | — | |
| Q2 2015 | +8.3% | — | — | |
| Q1 2015 | +7.2% | — | — | |
| Q4 2014 | -12.7% | — | — | |
| Q3 2014 | +8.3% | — | — | |
| Q2 2014 | -11.3% | — | — | |
| Q1 2014 | -20.2% | — | — | |
| Q4 2013 | +7.2% | — | — | |
| Q3 2013 | -3.3% | — | — | |
| Q2 2013 | +4.0% | — | — | |
| Q1 2013 | +7.6% | — | — | |
| Q4 2012 | +0.8% | — | — | |
| Q3 2012 | -6.2% | — | — | |
| Q2 2012 | +1.0% | — | — | |
| Q1 2012 | -0.4% | — | — | |
| Q4 2011 | +6.5% | — | — | |
| Q4 2009 | +6.5% | — | — | |
| Q3 2011 | -2.2% | — | — | |
| Q3 2010 | -2.2% | — | — | |
| Q4 2010 | -10.9% | — | — | |
| Q2 2011 | -10.9% | — | — | |
| Q2 2010 | -10.9% | — | — | |
| Q1 2011 | +1.7% | — | — | |
| Q1 2010 | +7.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro